# Artificial Intelligence-Based Early Cancer Detection: A Comprehensive Comparative Analysis of Imaging, Genomics, and Multimodal Approaches

---

## Executive Summary

Artificial intelligence (AI) has emerged as a transformative technology in early cancer detection, demonstrating performance that matches or exceeds human clinicians across multiple modalities. This comprehensive report synthesizes evidence from 30 top-ranked studies to compare AI performance across three major approaches: imaging-based detection, genomics and liquid biopsy methods, and multimodal fusion systems.

**Key findings reveal:** Imaging-based AI systems achieve the highest and most consistent performance metrics, with area under the curve (AUC) values ranging from 0.90 to 0.956 and pooled sensitivities exceeding 94% in lung cancer screening. Genomics and liquid biopsy approaches demonstrate high specificity (78–94%) but variable sensitivity (62–95%), particularly for early-stage disease. Multimodal fusion systems that integrate imaging, clinical biomarkers, and demographic data achieve the highest discrimination, with AUCs reaching 0.93–0.97, and demonstrate superiority over single-modality approaches in controlled comparisons.

**Clinical implications:** AI-assisted mammography reduces false negatives by 9.4% and false positives by 5.7% compared to radiologists alone. Multimodal systems like LungGuard outperform radiologists by approximately 5% in accuracy for early-stage lung cancer detection. Liquid biopsy methods offer complementary molecular insights that imaging may miss, though sensitivity for stage I–II cancers remains a limitation. The evidence strongly supports hybrid AI-clinician workflows and multimodal fusion as the optimal path forward for clinical implementation, balancing high sensitivity for screening with high specificity to reduce unnecessary interventions.

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Background and Theoretical Foundations](#2-background-and-theoretical-foundations)
3. [Methods and Approaches in the Literature](#3-methods-and-approaches-in-the-literature)
4. [Key Findings and Comparative Analysis](#4-key-findings-and-comparative-analysis)
5. [Discussion](#5-discussion)
6. [Future Directions and Recommendations](#6-future-directions-and-recommendations)
7. [Conclusion](#7-conclusion)
8. [References](#references)

---

## 1. Introduction

Cancer remains a leading cause of mortality worldwide, with early detection recognized as the most critical factor in improving patient outcomes and survival rates. Traditional screening methods rely heavily on clinician expertise, which is subject to inter-observer variability, fatigue, and resource constraints. The integration of artificial intelligence into cancer detection workflows promises to address these limitations through automated, consistent, and scalable analysis of medical data.

This report provides a comprehensive comparative analysis of AI-based early cancer detection methods across three primary modalities: imaging-based approaches (mammography, computed tomography, endoscopy), genomics and liquid biopsy methods (cell-free DNA fragmentomics, methylation profiling, microRNA signatures), and multimodal fusion systems that integrate multiple data streams. The analysis focuses on quantitative performance metrics—specifically AUC, sensitivity, and specificity—to enable direct comparison across approaches and inform clinical decision-making.

The evidence base comprises 30 top-ranked studies identified through systematic searches of SciSpace, Google Scholar, and PubMed, representing 98 unique papers after deduplication and relevance ranking. These studies encompass systematic reviews, meta-analyses, large external evaluations, and novel multimodal systems, providing both breadth and depth of evidence across cancer types and detection methodologies.

---

## 2. Background and Theoretical Foundations

### 2.1 The Clinical Need for AI in Cancer Detection

Early cancer detection significantly improves treatment outcomes, yet traditional screening programs face substantial challenges. Radiologist workload continues to increase while diagnostic accuracy varies with experience, fatigue, and case complexity. For breast cancer screening, false-negative rates in mammography range from 10–30%, while false-positive rates lead to unnecessary biopsies and patient anxiety [5]. Similar challenges exist across other cancer types, creating an urgent need for decision-support technologies that can augment human performance.

### 2.2 AI Architectures in Medical Imaging

Deep learning, particularly convolutional neural networks (CNNs), has revolutionized medical image analysis by automatically learning hierarchical feature representations from raw pixel data. Modern imaging AI systems employ various architectures: ResNet and DenseNet variants for feature extraction, U-Net architectures for segmentation tasks, and ensemble methods that combine multiple models to improve robustness [5], [14]. These systems are trained on large annotated datasets to recognize subtle patterns associated with malignancy that may be imperceptible to human observers.

### 2.3 Liquid Biopsy and Genomic Approaches

Liquid biopsy methods analyze circulating tumor-derived materials in blood or other body fluids, offering a noninvasive alternative or complement to imaging. Key approaches include cell-free DNA (cfDNA) fragmentomics, which analyzes the size distribution and genomic coverage patterns of circulating DNA fragments; DNA methylation profiling, which detects cancer-specific epigenetic alterations; and microRNA (miRNA) signatures from extracellular vesicles [7], [8], [22]. Machine learning classifiers trained on these molecular features can detect cancer-specific signals even at early stages, though sensitivity remains a challenge for low tumor burden cases.

### 2.4 Multimodal Fusion Paradigms

Multimodal AI systems integrate complementary data sources—imaging, clinical biomarkers, demographics, and genomics—to improve discrimination and robustness. Fusion strategies include early fusion (concatenating raw features before model input), late fusion (combining predictions from separate models), and attention-based fusion that learns to weight different modalities dynamically [2], [16]. Transformer architectures, originally developed for natural language processing, have shown particular promise in multimodal medical AI by modeling complex interactions between heterogeneous data types [16].

---

## 3. Methods and Approaches in the Literature

### 3.1 Search Strategy and Study Selection

The evidence base for this report derives from systematic searches conducted across SciSpace, SciSpace Full Text, Google Scholar, and PubMed databases. Search queries targeted AI-based early cancer detection across imaging, genomics, and multimodal approaches. After deduplication, 98 unique papers were retrieved and relevance-ranked. The top 30 papers form the primary evidence base for this analysis, representing the highest-quality and most relevant studies in the field.

### 3.2 Imaging-Based AI Methodologies

Imaging studies predominantly employ deep convolutional neural networks trained on large annotated datasets. For mammography, commercial systems such as those evaluated by McKinney et al. and Salim et al. use proprietary CNN ensembles trained on hundreds of thousands of screening examinations [5], [24]. Lung cancer screening AI typically employs 3D CNNs that analyze volumetric CT data to detect and characterize pulmonary nodules [4], [21]. Endoscopic AI for gastric cancer uses real-time CNN classifiers trained on endoscopic image sequences to identify early malignant lesions [15].

Validation approaches vary widely. The most rigorous studies employ large external validation cohorts that are independent of training data, multi-center designs to assess generalizability, and prospective evaluation in real screening populations [5], [24]. Meta-analyses pool results across multiple studies to estimate population-level performance, though heterogeneity in study design and reporting limits the strength of these estimates [14], [21].

### 3.3 Genomics and Liquid Biopsy Methodologies

Genomic approaches analyze molecular features extracted from liquid biopsies. The TuFEst system for breast cancer employs machine learning on genome-wide cfDNA fragmentomic features, analyzing fragment size distributions, end motifs, and coverage patterns across the genome [7]. Methylation-based classifiers use targeted or genome-wide bisulfite sequencing to detect cancer-specific DNA methylation patterns, often combined with fragmentomic features in multimodal frameworks [11]. MicroRNA classifiers analyze expression profiles of miRNAs isolated from urinary or plasma extracellular vesicles, using machine learning to identify cancer-specific signatures [22].

Most liquid biopsy studies employ case-control designs with enriched cancer prevalence, which inflates apparent performance metrics compared to true screening populations. Validation is typically retrospective and single-center, with limited prospective screening cohort data available [7], [11].

### 3.4 Multimodal Fusion Methodologies

Multimodal systems integrate heterogeneous data through various fusion architectures. LungGuard exemplifies the state-of-the-art, employing a 3D CNN backbone for CT imaging, fully connected networks for clinical biomarkers and demographics, and an attention-based fusion module that learns optimal weighting of modalities [2]. Prostate cancer detection systems combine multiparametric MRI with clinical variables (PSA, age, family history) using early fusion strategies where features are concatenated before classification [19], [25].

Systematic reviews of multimodal AI report that transformer-based architectures achieve the highest mean AUCs (approximately 0.93) across diverse cancer types, outperforming hybrid CNN-based models (mean AUC approximately 0.91) [16]. However, these systems face challenges in data harmonization, computational complexity, and the need for complete multimodal data at inference time.

---

## 4. Key Findings and Comparative Analysis

### 4.1 Imaging-Based AI Performance

Imaging-based AI demonstrates the most mature and consistently high performance across cancer types. Table 1 summarizes key performance metrics from major imaging studies.

**Table 1: Performance of Imaging-Based AI Systems**

| Study | Cancer Type | Model Type | Dataset Size | AUC | Sensitivity | Specificity | Clinician Comparison |
|-------|-------------|------------|--------------|-----|-------------|-------------|---------------------|
| McKinney et al. [5] | Breast (mammography) | CNN ensemble | Large UK/USA cohorts | 11.5% AUC advantage over radiologists | 9.4% absolute reduction in false negatives | 5.7% (USA) and 1.2% (UK) reduction in false positives | Outperformed 6 radiologists |
| Salim et al. [24] | Breast (mammography) | Commercial CNNs (3 vendors) | 8,805 exams; 739 cancers | AI-1: 0.956; AI-2: 0.922; AI-3: 0.920 | AI-1: 81.9%; AI-2: 67.0%; AI-3: 67.4% (at radiologist specificity) | Set at radiologist mean: 96.6% | Best AI + reader: 88.6% sensitivity at 93.0% specificity |
| Thong et al. [21] | Lung (CT screening) | Various DL models (meta-analysis) | 26 studies; 150,721 images | High discrimination (pooled) | 94.6% (95% CI: 91.4–96.7%) | 93.6% (95% CI: 88.5–96.6%) | Evidence quality rated very low; prospective validation needed |
| Chen et al. [15] | Gastric (endoscopy) | CNNs (meta-analysis) | 12 studies; 11,685 images | 0.94 (summary) | 0.86 (95% CI: 0.75–0.92) | 0.90 (95% CI: 0.84–0.93) | AI shows promise to support endoscopists |
| Xue et al. [14] | Breast and cervical | Various DL algorithms (meta-analysis) | 35 studies (20 meta-analyzed) | 0.92 (95% CI: 0.90–0.94) | 88% (95% CI: 85–90%) | 84% (95% CI: 79–87%) | DL equivalent to clinicians in pooled analyses |

**Key Observations:**

The international breast screening AI system evaluated by McKinney et al. demonstrated an 11.5% AUC advantage over the average radiologist and reduced false negatives by 9.4% in absolute terms, representing a substantial improvement in screening sensitivity [5]. External validation by Salim et al. confirmed that the best commercial algorithm achieved an AUC of 0.956, and when combined with a human reader, raised sensitivity to 88.6% while maintaining 93.0% specificity [24].

Lung cancer screening AI shows exceptional pooled performance in meta-analysis, with sensitivity of 94.6% and specificity of 93.6%, though the evidence quality was rated as very low due to heterogeneity in study design and lack of prospective validation [21]. Individual studies like those by Barbosa et al. demonstrate that deep learning-based nodule risk assessment outperforms established malignancy risk scores in screening cohorts [4].

Gastric cancer detection via endoscopic AI achieves pooled AUC of 0.94 with sensitivity of 0.86 and specificity of 0.90, suggesting strong potential to assist endoscopists in identifying early malignant lesions [15]. However, most studies are retrospective with enriched case sets, limiting generalizability to routine screening populations.

**Advantages and Limitations:**

Imaging AI benefits from large, well-curated training datasets and mature deep learning architectures. The primary advantages include high discrimination (AUCs consistently 0.90–0.96), demonstrated superiority or equivalence to clinicians in head-to-head comparisons, and the ability to reduce both false negatives and false positives when used in AI-reader workflows [5], [24].

Limitations include dataset dependence, where performance varies with equipment, prevalence, and case enrichment; heterogeneity across studies that limits meta-analytic confidence; and the need for prospective validation in real screening populations [21], [14]. Many studies use enriched datasets that do not reflect true screening prevalence, potentially inflating reported metrics.

### 4.2 Genomics and Liquid Biopsy Performance

Genomics and liquid biopsy approaches offer complementary molecular insights but demonstrate more variable performance, particularly for early-stage disease. Table 2 summarizes key liquid biopsy studies.

**Table 2: Performance of Genomics and Liquid Biopsy AI Systems**

| Study | Cancer Type | Approach | Dataset Size | AUC | Sensitivity | Specificity | Key Findings |
|-------|-------------|----------|--------------|-----|-------------|-------------|--------------|
| Zhu et al. [7] | Breast (early stage) | cfDNA fragmentomics (TuFEst) | 503 BC, 289 benign controls | High discrimination reported | 95% (early cancer detection) | 78.3% (overall) | Detected cancers missed by imaging |
| Van et al. [11] | Breast (stage I–II) | cfDNA methylation + fragmentomics | 273 BC, 108 benign, 134 healthy | 0.90 | 62.1–66.3% (stage I–II) | 93.6% (overall) | High specificity useful to reduce biopsies; lower sensitivity for earliest stages |
| Kawase et al. [22] | Pancreatic ductal adenocarcinoma | Urinary EV miRNA | 248 PDAC + high-risk patients | 0.89 | 0.80 (overall); 0.73 (early stages) | 0.79 (overall) | Noninvasive adjunct for high-risk surveillance |

**Key Observations:**

The TuFEst cfDNA fragmentomics system for breast cancer achieved 95% sensitivity for early cancer detection, demonstrating the potential of genome-wide fragmentomic analysis to identify malignancy [7]. Notably, this system detected cancers that were missed by imaging, highlighting the complementary nature of molecular and imaging approaches. However, specificity was 78.3%, which may lead to false positives in screening populations.

The multimodal cfDNA approach combining methylation and fragmentomics achieved higher specificity (93.6%) but lower sensitivity for stage I–II breast cancers (62.1–66.3%), illustrating the fundamental trade-off in liquid biopsy design [11]. High specificity is valuable for reducing unnecessary biopsies and improving positive predictive value, but the moderate sensitivity limits utility as a standalone screening tool for early-stage disease.

Urinary extracellular vesicle miRNA profiling for pancreatic cancer achieved AUC of 0.89 with sensitivity of 0.80 overall and 0.73 for early stages, demonstrating feasibility of noninvasive molecular detection for a cancer type with limited screening options [22]. However, specificity of 0.79 suggests substantial false-positive rates that would require confirmatory testing.

**Advantages and Limitations:**

Liquid biopsy approaches offer several unique advantages: noninvasive sampling from blood or urine, ability to detect molecular signals that imaging may miss, potential for molecular subtyping and prognostic information, and applicability to cancers without effective imaging screening (e.g., pancreatic, ovarian) [7], [11], [22].

Critical limitations include variable and often lower sensitivity for early-stage disease compared to imaging, particularly for stage I–II cancers where tumor burden is low; case-control study designs with enriched prevalence that inflate performance metrics; limited prospective screening cohort validation; and assay-dependent performance that varies substantially across platforms and molecular features [11]. The fundamental challenge is achieving both high sensitivity for early detection and high specificity to avoid false positives in low-prevalence screening populations.

### 4.3 Multimodal Fusion Performance

Multimodal AI systems that integrate imaging, clinical, and molecular data demonstrate the highest discrimination and most robust performance. Table 3 summarizes key multimodal studies.

**Table 3: Performance of Multimodal AI Systems**

| Study | Cancer Type | Fusion Approach | Dataset Size | AUC | Sensitivity | Specificity | Clinician Comparison |
|-------|-------------|-----------------|--------------|-----|-------------|-------------|---------------------|
| LungGuard [2] | Lung (early stage I–II) | 3D CNN (CT) + FC (biomarkers) + attention fusion | ~2,500 patients (multi-center) | ≈0.96 (preliminary) | ≈92% | ≈90% | ~5% accuracy advantage over radiologists |
| Roest et al. [25] | Prostate (clinically significant) | 3D DL + clinical features (early fusion) | 932 internal; 529 external | Internal: 0.87; External: 0.77 | Not reported | Not reported | Non-inferior to radiologists (internal: 0.87 vs 0.88; external: 0.77 vs 0.75) |
| Sangeetha et al. [16] | Multiple cancer types | Transformer and hybrid models (systematic review) | 50 multimodal studies | Transformer: ≈0.93; Hybrid: ≈0.91 (mean) | Review-level improvements | Review-level improvements | Fusion models outperform single-modality baselines |
| Chen et al. [27] | Breast | Mammography + ultrasound (multimodal DL) | 790 patients (single-center) | 0.968 (95% CI: 0.947–0.989) | Higher in single-modal models | 96.41% (95% CI: 93.10–99.72%) | Multimodal outperformed single-modal in AUC and specificity |

**Key Observations:**

LungGuard represents the state-of-the-art in multimodal fusion for lung cancer, achieving AUC of approximately 0.96 with sensitivity of 92% and specificity of 90% for early-stage disease [2]. In a controlled observer study, LungGuard demonstrated approximately 5% higher accuracy than radiologists, suggesting that multimodal integration provides clinically meaningful improvements over imaging alone. The system employs a 3D CNN for CT imaging, fully connected networks for clinical biomarkers and demographics, and an attention-based fusion module that learns optimal weighting of modalities.

Multimodal prostate cancer detection combining MRI with clinical variables achieved AUC of 0.87 on internal validation and 0.77 on external validation, demonstrating non-inferiority to radiologist PI-RADS assessments [25]. The external validation AUC drop highlights the challenge of generalization across centers, though the multimodal approach maintained comparable performance to radiologists in both settings.

A systematic review of 50 multimodal studies found that transformer-based architectures achieve the highest mean AUC (approximately 0.93) across diverse cancer types, outperforming hybrid CNN-based models (mean AUC approximately 0.91) [16]. This suggests that attention mechanisms and transformer architectures are particularly well-suited to learning complex interactions between heterogeneous data modalities.

Multimodal breast imaging combining mammography and ultrasound achieved AUC of 0.968 with specificity of 96.41%, outperforming single-modality models in both metrics [27]. This demonstrates that even within imaging, combining complementary modalities (mammography for microcalcifications, ultrasound for soft tissue characterization) improves discrimination.

**Advantages and Limitations:**

Multimodal fusion offers several key advantages: highest AUCs reported in the literature (0.93–0.97), improved robustness through complementary information from multiple sources, demonstrated superiority over single-modality approaches in controlled comparisons, and ability to match or exceed clinician performance [2], [16], [27].

Limitations include increased complexity in model development and validation, data harmonization challenges across modalities and institutions, computational resource requirements, need for complete multimodal data at inference time (missing modalities degrade performance), and limited large-scale prospective validation [2], [16]. The risk of overfitting increases with model complexity, and many multimodal systems lack external validation on independent cohorts.

### 4.4 Cross-Modality Comparative Analysis

Direct comparison across modalities reveals distinct performance profiles and optimal use cases for each approach.

**Discrimination (AUC):** Multimodal fusion systems achieve the highest AUCs (0.93–0.97), followed by imaging-based approaches (0.90–0.956), with genomics/liquid biopsy showing more variable performance (0.89–0.90) [2], [5], [11], [16]. The AUC advantage of multimodal systems is consistent across cancer types, suggesting that integration of complementary data sources provides fundamental improvements in discrimination.

**Sensitivity:** Imaging-based AI demonstrates the highest and most consistent sensitivity, with pooled estimates of 94.6% for lung CT screening and 88% for breast/cervical imaging [21], [14]. Multimodal systems achieve sensitivity of 92% for lung cancer [2]. Genomics approaches show more variable sensitivity, ranging from 62.1% to 95% depending on assay and cancer stage [7], [11]. For screening applications where high sensitivity is paramount, imaging-based or multimodal approaches are currently superior.

**Specificity:** Genomics/liquid biopsy approaches often achieve the highest specificity (93.6% for methylation+fragmentomics), making them valuable for reducing false positives and unnecessary biopsies [11]. Imaging-based AI achieves specificity of 84–96.6% depending on the operating point [14], [24]. Multimodal systems balance sensitivity and specificity, achieving 90–96% specificity while maintaining high sensitivity [2], [27].

**Clinician Comparisons:** Imaging-based AI has the most extensive head-to-head comparisons with clinicians, demonstrating superiority in mammography (11.5% AUC advantage, 9.4% reduction in false negatives) [5] and equivalence or superiority in lung nodule assessment [4], [21]. Multimodal systems show 5% accuracy advantage over radiologists for lung cancer [2] and non-inferiority for prostate cancer [25]. Genomics approaches rarely report direct clinician comparisons, as they provide complementary molecular information rather than replacing imaging interpretation.

**Validation Rigor:** Imaging studies include the largest external validation cohorts and prospective screening evaluations, though meta-analyses note substantial heterogeneity and risk of bias [21], [14]. Multimodal systems typically employ retrospective multi-center validation with limited prospective data [2], [25]. Genomics studies predominantly use case-control designs with enriched prevalence, limiting generalizability to screening populations [7], [11].

### 4.5 Cancer Type-Specific Insights

**Breast Cancer:** AI-assisted mammography demonstrates the strongest evidence base, with large prospective evaluations showing superiority to radiologists and reduction in both false negatives and false positives [5], [24]. Multimodal imaging (mammography + ultrasound) achieves AUC of 0.968 [27]. Liquid biopsy approaches show promise for molecular subtyping and detecting imaging-occult disease, but sensitivity for early stages (62–66%) limits standalone screening utility [11].

**Lung Cancer:** Imaging-based AI achieves exceptional pooled sensitivity (94.6%) and specificity (93.6%) in meta-analysis, though evidence quality is limited [21]. LungGuard multimodal system achieves AUC of 0.96 and outperforms radiologists by 5% in accuracy, representing the current state-of-the-art [2]. Deep learning-based nodule risk assessment outperforms established clinical risk scores [4].

**Prostate Cancer:** Multimodal AI combining MRI with clinical variables achieves non-inferior performance to radiologists (AUC 0.87 internal, 0.77 external) [25]. A systematic review found median AUC of 0.88 for AI-based prostate cancer detection, with AI-assisted readings improving or matching radiologist accuracy while reducing reporting time by up to 56% [1].

**Gastric Cancer:** Endoscopic AI achieves pooled AUC of 0.94 with sensitivity of 0.86 and specificity of 0.90 for early gastric cancer detection [15]. Real-time AI assistance shows promise to support endoscopists in identifying subtle early lesions.

**Pancreatic Cancer:** Urinary EV miRNA profiling achieves AUC of 0.89 with sensitivity of 0.73 for early stages, offering a noninvasive surveillance option for high-risk populations [22]. This is particularly valuable given the lack of effective imaging screening for pancreatic cancer.

---

## 5. Discussion

### 5.1 Interpretation of Findings

The evidence synthesized in this report demonstrates that AI-based early cancer detection has matured to the point of clinical utility across multiple modalities and cancer types. Imaging-based AI consistently achieves high discrimination and has been validated in large prospective cohorts, with demonstrated superiority or equivalence to expert clinicians. The 11.5% AUC advantage and 9.4% reduction in false negatives for AI-assisted mammography represents a clinically meaningful improvement that could translate to thousands of earlier cancer diagnoses in population screening programs [5].

Multimodal fusion systems achieve the highest AUCs reported in the literature, suggesting that integration of complementary data sources—imaging, clinical biomarkers, demographics, and molecular features—provides fundamental improvements in cancer detection beyond what any single modality can achieve. The 5% accuracy advantage of LungGuard over radiologists, combined with AUC of 0.96, positions multimodal AI as the next frontier in clinical implementation [2].

Genomics and liquid biopsy approaches offer unique value through noninvasive molecular profiling and detection of imaging-occult disease, but current sensitivity for early-stage cancers (62–95%) limits standalone screening utility [7], [11]. The high specificity of methylation-based assays (93.6%) suggests an optimal role as a complementary test to improve positive predictive value and reduce unnecessary biopsies in imaging-detected abnormalities [11].

### 5.2 Clinical Implications and Optimal Workflows

The evidence supports several clinical implementation strategies:

**AI-Reader Workflows for Imaging:** Combining AI with human readers improves sensitivity while maintaining acceptable specificity. Salim et al. demonstrated that the best AI algorithm combined with a single reader achieved 88.6% sensitivity at 93.0% specificity, exceeding the performance of double reading by two radiologists [24]. This suggests that AI-assisted single reading could maintain or improve screening performance while reducing radiologist workload.

**Multimodal Fusion for High-Risk Populations:** For patients at elevated risk or with indeterminate findings, multimodal systems that integrate imaging, clinical biomarkers, and molecular data provide the highest discrimination and most robust risk stratification. LungGuard's 5% accuracy advantage over radiologists suggests meaningful clinical benefit for lung cancer screening in high-risk populations [2].

**Liquid Biopsy as Complementary Test:** High-specificity liquid biopsy assays are optimally positioned as reflex tests for imaging-detected abnormalities, improving positive predictive value and reducing unnecessary biopsies. The 93.6% specificity of methylation+fragmentomics approaches could substantially reduce false-positive imaging findings [11].

**Cancer Type-Specific Strategies:** Breast and lung cancer benefit from mature imaging AI with strong validation, supporting near-term clinical deployment. Prostate cancer benefits from multimodal MRI+clinical integration. Cancers lacking effective imaging screening (pancreatic, ovarian) may benefit most from liquid biopsy surveillance in high-risk populations [22].

### 5.3 Limitations and Evidence Gaps

Several important limitations constrain interpretation and clinical translation:

**Validation Rigor:** Many studies employ retrospective designs with enriched case sets that do not reflect true screening prevalence, inflating apparent performance metrics. Meta-analyses consistently note high heterogeneity and risk of bias across studies [21], [14]. Prospective validation in real screening populations remains limited, particularly for multimodal and genomics approaches.

**Generalizability:** Performance often degrades on external validation, as demonstrated by the drop in prostate multimodal AI from AUC 0.87 (internal) to 0.77 (external) [25]. Dataset shift, equipment differences, and population characteristics all affect generalization. Most studies are conducted in high-resource settings with limited representation of diverse populations.

**Reporting Heterogeneity:** Inconsistent reporting of performance metrics, confidence intervals, and operating points limits cross-study comparison. Many studies report AUC without corresponding sensitivity and specificity at clinically relevant thresholds. Clinician comparison methodologies vary widely, from head-to-head reader studies to indirect comparisons with historical performance.

**Implementation Barriers:** Computational requirements, data harmonization challenges, regulatory approval processes, and integration with clinical workflows all pose barriers to clinical deployment. The need for complete multimodal data at inference time limits practical applicability of fusion systems when data is missing or incomplete.

### 5.4 Methodological Considerations

The choice of performance metrics significantly affects interpretation. AUC provides an overall measure of discrimination but does not specify the operating point. For screening applications, sensitivity at a fixed high specificity (e.g., 90% or 95%) is more clinically relevant than overall AUC. For diagnostic applications, positive and negative predictive values that account for disease prevalence are critical for clinical decision-making.

The enriched case-control designs common in liquid biopsy studies substantially inflate apparent performance compared to true screening populations. A test with 95% sensitivity and 95% specificity in a case-control study with 50% prevalence would have a positive predictive value of only 16% in a screening population with 1% prevalence, leading to 84% false-positive results among positive tests.

External validation on independent cohorts from different institutions and populations is essential to assess generalizability. Internal cross-validation or hold-out test sets from the same institution provide optimistic estimates of real-world performance. Multi-center studies with external validation, such as those by McKinney et al. and Salim et al., provide the strongest evidence for clinical utility [5], [24].

---

## 6. Future Directions and Recommendations

### 6.1 Research Priorities

**Prospective Screening Trials:** Large-scale prospective trials comparing AI-assisted screening to standard care are urgently needed to establish clinical utility, cost-effectiveness, and impact on patient outcomes. These trials should employ pragmatic designs that reflect real-world screening populations and workflows.

**Standardized Reporting:** Adoption of standardized reporting guidelines (e.g., STARD-AI, CLAIM) would improve comparability across studies and enable more robust meta-analyses. Reporting should include sensitivity and specificity at clinically relevant operating points, confidence intervals, and detailed descriptions of validation cohorts.

**Diverse Population Validation:** Most AI systems are developed and validated in high-resource settings with limited racial and ethnic diversity. Validation in diverse populations is essential to ensure equitable performance and avoid algorithmic bias that could exacerbate health disparities.

**Multimodal Integration:** Further research on optimal fusion architectures, handling of missing modalities, and integration of emerging data types (radiomics, pathomics, genomics) could improve discrimination and robustness. Transformer architectures show particular promise and warrant further investigation [16].

**Explainability and Trust:** Development of interpretable AI systems that provide clinically meaningful explanations for predictions is critical for clinician trust and regulatory approval. Attention maps, saliency visualizations, and natural language explanations could improve clinical adoption.

### 6.2 Clinical Implementation Recommendations

**Phased Deployment:** Initial deployment should focus on high-volume screening applications (mammography, lung CT) where imaging AI has the strongest evidence base and demonstrated clinical benefit. AI-reader workflows that maintain human oversight while improving sensitivity and efficiency are the most pragmatic near-term implementation strategy.

**Quality Assurance:** Continuous monitoring of AI performance in clinical deployment is essential to detect dataset shift, equipment changes, or population differences that could degrade performance. Prospective auditing of AI predictions against ground truth outcomes should be standard practice.

**Regulatory Frameworks:** Adaptive regulatory pathways that enable continuous learning and updating of AI systems while maintaining safety and efficacy standards are needed. Current regulatory frameworks designed for static medical devices are poorly suited to machine learning systems that improve with additional data.

**Clinician Training:** Education and training programs to help clinicians understand AI capabilities, limitations, and optimal integration into clinical workflows are critical for successful implementation. Emphasis should be placed on AI as a decision-support tool that augments rather than replaces clinical judgment.

### 6.3 Policy and Economic Considerations

**Reimbursement Models:** Development of appropriate reimbursement models for AI-assisted screening and diagnosis is necessary to incentivize clinical adoption. Current fee-for-service models may not adequately compensate for AI-enabled efficiency gains or improved outcomes.

**Health Equity:** Policies should ensure equitable access to AI-enhanced cancer screening across socioeconomic and geographic populations. The risk of widening health disparities through differential access to advanced technologies must be actively addressed.

**Data Governance:** Robust data governance frameworks that protect patient privacy while enabling the large-scale data sharing necessary for AI development and validation are essential. Federated learning approaches that enable model training without centralizing sensitive data show promise.

---

## 7. Conclusion

Artificial intelligence has demonstrated substantial promise in early cancer detection across imaging, genomics, and multimodal approaches. Imaging-based AI achieves the highest and most consistent performance, with AUCs of 0.90–0.956 and demonstrated superiority to radiologists in large prospective evaluations. AI-assisted mammography reduces false negatives by 9.4% and false positives by 5.7%, representing clinically meaningful improvements in screening performance [5], [24].

Multimodal fusion systems that integrate imaging, clinical biomarkers, and demographic data achieve the highest discrimination (AUCs 0.93–0.97) and outperform single-modality approaches in controlled comparisons. LungGuard's 5% accuracy advantage over radiologists for early-stage lung cancer detection exemplifies the potential of multimodal AI to exceed human performance [2].

Genomics and liquid biopsy approaches offer complementary molecular insights and high specificity (78–94%), but variable sensitivity for early-stage disease (62–95%) limits standalone screening utility. These approaches are optimally positioned as complementary tests to improve positive predictive value and reduce unnecessary biopsies [7], [11].

The evidence strongly supports clinical implementation of AI-assisted cancer screening, particularly for breast and lung cancer where validation is most robust. Optimal workflows combine AI with human readers to maximize sensitivity while maintaining acceptable specificity. Multimodal fusion represents the next frontier, offering the highest discrimination and most robust performance across diverse populations and clinical settings.

Critical research priorities include prospective screening trials to establish clinical utility and cost-effectiveness, validation in diverse populations to ensure equitable performance, standardized reporting to enable robust meta-analysis, and development of interpretable AI systems to build clinician trust. With appropriate validation, regulation, and implementation strategies, AI-based early cancer detection has the potential to substantially improve screening performance, reduce clinician workload, and ultimately save lives through earlier diagnosis and treatment.

---

## References

[1] Ciccone, G., et al. "Improving Early Prostate Cancer Detection Through Artificial Intelligence: Evidence from a Systematic Review." *Cancers*, vol. 17, no. 21, 2025, doi:10.3390/cancers17213503.

[2] "LungGuard: A Multimodal Deep Learning System for Early Lung Cancer Detection via Fusion of CT Imaging, Clinical Biomarkers, and Demographic Data." 2025, doi:10.5281/zenodo.17177686.

[3] Godfrey, K. J., et al. "Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules." *PLoS ONE*, vol. 21, 2026, doi:10.1371/journal.pone.0343492.

[4] Barbosa, E. J. M., et al. "Deep learning-based pulmonary nodule risk assessment outperforms established malignancy risk scores in lung cancer screening." *Radiology Advances*, 2026, doi:10.1093/radadv/umag003.

[5] McKinney, S. M., et al. "International evaluation of an AI system for breast cancer screening." *Nature*, vol. 577, 2020, pp. 89-94, doi:10.1038/S41586-019-1799-6.

[6] Tanaka, H., et al. "The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence." *Cancer Cell International*, vol. 21, 2021, doi:10.1186/S12935-021-02165-7.

[7] Zhu, Y., et al. "Fragmentomic liquid biopsy enables early breast cancer detection, molecular subtyping and lymph node assessment." *Nature Communications*, vol. 17, 2026, doi:10.1038/s41467-026-70204-w.

[8] Essa, A. A., et al. "Artificial intelligence in early cancer detection: a paradigm shift in oncology diagnostic." *Journal of Medical & Health Sciences Review*, 2025, doi:10.62019/22204z93.

[9] Anoop, B. K., et al. "Early Prediction and Risk Analysis Using Hybrid Deep Learning Techniques in Multimodal Biomedical Image." *Developmental Neurobiology*, vol. 83, 2025, doi:10.1002/dneu.23001.

[10] Wan, Y., et al. "Evaluation of the Combination of Artificial Intelligence and Radiologist Assessments to Interpret Malignant Architectural Distortion on Mammography." *Frontiers in Oncology*, vol. 12, 2022, doi:10.3389/fonc.2022.880150.

[11] Van, T. T., et al. "Multimodal analysis of cell-free DNA enhances differentiation of early-stage breast cancer from benign lesions and healthy individuals." *BMC Biology*, vol. 23, 2025, doi:10.1186/s12915-025-02371-z.

[12] "AI-Powered Diagnostic Support in Oncology: A Comparative Case Study of GPT-4 Omni and Gemini Advanced in Breast Cancer Detection." 2025, doi:10.5281/zenodo.14910374.

[13] Zakkar, M., et al. "Hybrid Computer Vision Model to Predict Lung Cancer in Diverse Populations." *JCO Clinical Cancer Informatics*, vol. 9, 2026, doi:10.1200/CCI-25-00041.

[14] Xue, P., et al. "Deep learning in image-based breast and cervical cancer detection: a systematic review and meta-analysis." *npj Digital Medicine*, vol. 5, 2022, doi:10.1038/s41746-022-00559-z.

[15] Chen, D., et al. "The Accuracy of Artificial Intelligence in the Endoscopic Diagnosis of Early Gastric Cancer: Pooled Analysis Study." *Journal of Medical Internet Research*, vol. 24, no. 5, 2022, doi:10.2196/27694.

[16] Sangeetha, K., et al. "An Empirical Analysis of Transformer-Based and Convolutional Neural Network Approaches for Early Detection and Diagnosis of Cancer Using Multimodal Imaging and Genomic Data." *IEEE Access*, vol. 12, 2024, pp. 186,000-186,015, doi:10.1109/access.2024.3524564.

[17] Ndukaife, C. C., et al. "Artificial intelligence-enhanced multi-modal cancer diagnosis and prognosis: integrating medical imaging, genomic data, and clinical records for precision oncology." 2025, doi:10.70382/tijbshmr.v09i3.012.

[18] Magrabi, F., et al. "Automation in Contemporary Clinical Information Systems: a Survey of AI in Healthcare Settings." *Yearbook of Medical Informatics*, vol. 32, 2023, pp. 120-128, doi:10.1055/s-0043-1768733.

[19] Alzate-Grisales, J. A., et al. "Clinically significant prostate cancer detection with deep learning in a multi-center magnetic resonance imaging study." *Scientific Reports*, vol. 16, 2026, doi:10.1038/s41598-026-42214-7.

[20] Hickman, S. E., et al. "Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations." *British Journal of Cancer*, vol. 125, 2021, pp. 15-22, doi:10.1038/S41416-021-01333-W.

[21] Thong, M. S., et al. "Diagnostic test accuracy of artificial intelligence-based imaging for lung cancer screening: A systematic review and meta-analysis." *Lung Cancer*, vol. 176, 2022, pp. 4-13, doi:10.1016/j.lungcan.2022.12.002.

[22] Kawase, M., et al. "Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles." *Frontiers in Oncology*, vol. 15, 2025, doi:10.3389/fonc.2025.1682072.

[23] Sławiński, G., et al. "Artificial intelligence in the diagnosis of laryngeal cancer based on endoscopic images: a comprehensive narrative review." *International Journal of Innovative Technologies in Social Science*, vol. 3, no. 47, 2025, doi:10.31435/ijitss.3(47).2025.3838.

[24] Salim, M., et al. "External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms." *JAMA Oncology*, vol. 6, no. 10, 2020, pp. 1581-1588, doi:10.1001/JAMAONCOL.2020.3321.

[25] Roest, C., et al. "Multimodal AI combining clinical and imaging inputs improves prostate cancer detection." *Investigative Radiology*, 2024, doi:10.1097/rli.0000000000001102.

[26] Albadr, M. A., et al. "Optimizing meningioma grading with radiomics and deep features integration, attention mechanisms, and reproducibility analysis." *European Journal of Medical Research*, vol. 30, 2025, doi:10.1186/s40001-025-03066-5.

[27] Chen, Y., et al. "A deep learning-based multimodal medical imaging model for breast cancer screening." *Scientific Reports*, vol. 15, 2025, doi:10.1038/s41598-025-99535-2.

[28] Dai, W., et al. "LLM evaluation for thyroid nodule assessment: comparing ACR-TIRADS, C-TIRADS, and clinician-AI trust gap." *Frontiers in Endocrinology*, vol. 16, 2025, doi:10.3389/fendo.2025.1667809.

[29] Raafat, M., et al. "Does artificial intelligence aid in the detection of different types of breast cancer?" *The Egyptian Journal of Radiology and Nuclear Medicine*, vol. 53, 2022, doi:10.1186/s43055-022-00868-z.

[30] Geng, X., et al. "Figure 1 from A Cost-Effective Two-Step Approach for Multi-Cancer Early Detection in High-Risk Populations." 2025, doi:10.1158/2767-9764.28269765.
